Navigation Links
Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
Date:1/27/2009

WAYNE, Pa., Jan. 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced the signing of $3.1 million of new business awards, primarily consisting of an extension of a current U.S. oncology clinical trial with a major global pharmaceutical company to be conducted in the U.S. and Europe. The extension increases the value of the contract from $12.4 million to $14.4 million.

At December 31, 2008, the Company had a backlog of approximately $35 million.

Dr. David Ginsberg, President and CEO of Encorium Group, Inc. stated, "We see this as a great confirmation of our growing success in the field of oncology. Being entrusted to conduct the expansion of this large oncology trial is an important acknowledgment by the trial's sponsor of the high quality of our work. We are proud of the continuous first class performance of our oncology team. Further, the new business awards announced today mitigate any negative impact to our backlog as reported at December 31, 2008 from foreign currency translations, contract terminations and revenue recognized."

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug a
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
4. Intelligroup Secures Multi-Million Dollar COSMOS Implementation with Almac Clinical Services
5. Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
6. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
7. Perceptive Informatics Enters License Agreement With EuroQoL Group to Provide Enhanced Standardization for ePRO Solution
8. Norton & Associates Inc. Adds $3bnUSD Commercial Real Estate Investment P & L Management Holding Group; US Property Portfolio Inc.
9. Health Robotics Announces Partnership in the Peoples Republic of China With The Devon International Group
10. Investor Group Reconfigures Proposed Slate of Replacement Directors for Trinity Biotech
11. Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PA (PRWEB) July 30, 2014 Vycom ... family of products, designed to meet Factory Mutual (FM) ... equipment materials such as wet benches, process tools, fume ... worker safety and damage to semiconductor wafers used in ... provides a flame-retardant PVC solution with excellent workability and ...
(Date:7/30/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), is ... technologies are used to discover, develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... Vice President and Chief Financial Officer. Tom will ... technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. (OTCBB: ... and development of compounds to safely regress atherosclerotic ... announces that its partner, CardioNova, has accomplished first ... trial with AtheroNova,s lead compound, AHRO-001.  This Phase ... AHRO-001 Phase 1 safety trial completed in February ...
(Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
Breaking Biology Technology:Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... in Alexandria, VA, the Department of Health and Human ... Accountability (OGAPA) recognized the National Institutes of Health,s Commercialization ... special "team" recognition award for superior efforts to assist ... and "contributing to public health." The award was made ...
... TORONTO, ON Scientists at the University of Toronto, Stanford ... action and function of candidate prescription drugs on human cells, ... a larger scale than ever before. The researchers say ... understanding of a variety of diseases and biologic actions, and ...
... in the Materials Science and Technology division of ... injection, detection and precession of spin accumulation in ... at temperatures up to 225 degrees Celsius. These ... in Si is viable as a basis for ...
Cached Biology Technology:Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium 2University of Toronto chemistry technology promises more effective prescription drug therapies 2NRL scientists achieve high temperature milestone in silicon spintronics 2NRL scientists achieve high temperature milestone in silicon spintronics 3
(Date:7/30/2014)... Oxford University Press (OUP) is pleased to announce its ... Beginning in 2015, OUP and CINP will partner to ... ) as a fully open-access journal. , Alan Frazer, ... that the size and expertise of OUP will further ... become one of the very leading journals within neuropsychopharmacology. ...
(Date:7/30/2014)... received a pledge of $1 million from the Cornelia ... new Neurobehavioral Biometry Center. , The newly ... the Laboratory to develop a greater breadth and depth ... of accelerating the pace of research to improve human ... premier resource for the Laboratory and its external partners, ...
(Date:7/30/2014)... as simple as inserting a medicated, disappearing fabric minutes ... have discovered a potentially faster way to deliver a ... method spins the drug into silk-like fibers that quickly ... of the drug than possible with other topical materials ... women a potentially more effective, discreet way to protect ...
Breaking Biology News(10 mins):OUP to partner with the International College of Neuropsychopharmacology 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... frogs like to ,see what they,re getting, when they select ... Michael Reichert from the University of Wisconsin-Milwaukee in the US. ... the importance of vision on male mating behaviors in a ... journal Behavioral Ecology and Sociobiology . Animals display ...
... Shenzhen, China An international research team led by ... genomic sequence of pear by an approach using the ... genome not only provides an invaluable new resource for ... new light on the genome evolution and other genome-wide ...
... 2012 Medbox, Inc. (Ticker: MDBX) ( www.medboxinc.com ), ... have received many inquiries from shareholders purchasing shares of ... volatile trading. These inquiries were responded to and shareholders ... In other news, the company further ...
Cached Biology News:Vision stimulates courtship calls in the grey tree frog 2Pear genome provides new insight into breeding improvement and evolutionary trace analysis 2Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel 2
... SeeDNA co-precipitant, 250 ... pink color ensures easy ... nucleic acid recovery.Chemically inert, ... biology applications.Simple 5-minute protocol. ...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Request Info...
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Biology Products: